Camber1jpj (Camber1jpg)
Tadalafil Tablet, Film Coated
Product Images NDC 50090-6945
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-6945). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Label Image (Lbl500906945)
Label for Tadalafil 5 mg film-coated oral tablets by A-S Medication Solutions. The label notes that each film-coated tablet contains 5 mg of Tadalafil USP and includes storage instructions to keep at 68 to 77 degrees Fahrenheit. The package contains 90 tablets and provides a dosage instruction to see the package insert.*
Tadalafilfigure1.jpg (Tadalafilfigure1)
Four line graphs showing the difference in blood pressure (systolic and diastolic) between tadalafil and placebo over time (hours). The graphs include Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP, each with error bars across time points from 0 to 96 hours.*
Tadalafilfigure2.jpg (Tadalafilfigure2)
Two line graphs showing changes in systolic blood pressure (mmHg) over 24 hours post-dose. The top graph depicts standing systolic blood pressure, comparing Tadalafil 20 mg with doxazosin 8 mg against placebo with doxazosin 8 mg. The bottom graph shows supine systolic blood pressure over the same time period for the same treatments.*
Tadalafilfigure4.jpg (Tadalafilfigure4)
A line graph showing the effect of tadalafil and placebo on systolic blood pressure over 12 hours. The graph compares four groups: 20 mg tadalafil taken at 08:00 with 8 mg doxazosin, placebo taken at 08:00 with 8 mg doxazosin, 20 mg tadalafil taken at 20:00 with 8 mg doxazosin, and placebo taken at 20:00 with 8 mg doxazosin. The vertical axis measures systolic blood pressure changes in mmHg, and the horizontal axis shows time after administration in hours.*
Tadalafilfigure5.jpg (Tadalafilfigure5)
A line graph showing plasma tadalafil concentration (μg/L) over time (hours) for three dosing regimens: single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The graph includes data points with error bars indicating variability at each time point.*
Tadalfilfigure6.jpg (Tadalafilfigure6)
A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment for Tadalafil 5 mg versus placebo. The graph shows a greater reduction in IPSS score with Tadalafil compared to placebo, with markers at 0, 4, 8, and 12 weeks. Statistical significance is indicated at p<0.01.*
Tadalafilfigure7.jpg (Tadalafilfigure7)
A line graph showing the change from baseline in IPSS total score over a 12-week treatment duration. The graph compares Tadalafil 5 mg and placebo groups, with data points at 0, 1, 4, 8, and 12 weeks. A statistically significant difference (p<0.01) is indicated at several time points favoring Tadalafil.*
Tadalafilfigure8 (Tadalafilfigure8)
A line graph titled 'Weeks of Therapy' showing LS Mean Change from Baseline on the vertical axis and weeks (0, 4, 12, 26) on the horizontal axis. It compares Tadalafil/Finasteride and Placebo/Finasteride groups, illustrating treatment differences over time with significance markers (p<0.001 and p<0.05).*
Tadalfilfigure9.jpg (Tadalafilfigure9)
Line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil and placebo groups. The x-axis shows duration of treatment in weeks (0 to 12), and the y-axis shows the change from baseline in IPSS total score, with Tadalafil showing a greater decrease compared to placebo.*
Tadalafilstructure.jpg (Tadalafilstructure)
Chemical structure diagram of Tadalafil, displaying its molecular arrangement with rings and functional groups as illustrated.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
